US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
| FOSAMAX PLUS D | EQ 70MG BASE;2,800 IU; EQ 70MG BASE;5,600 IU | tablet · oral | ORGANON LLC | Prescription | 7 Apr 2005 |
EMA European Union — centrally authorised medicines
Fosavance Organon N.V. · Authorised · authorised 24 Aug 2005 · ATC M05BB03
Therapeutic indication (EMA)
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Fosavance reduces the risk of vertebral and hip fractures.
Adrovance Organon N.V. · Authorised · authorised 4 Jan 2007 · ATC M05BB03
Therapeutic indication (EMA)
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Adrovance reduces the risk of vertebral and hip fractures.
Therapeutic indication (EMA)
Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures. Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency. Vantavo reduces the risk of vertebral and hip fractures.
Therapeutic indication (EMA)
Treatment of postmenopausal osteoporosis
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
| US NADAC | FOSAMAX PLUS D 70 MG-2800 UNIT | $52.5645 | per EA | 23 Sep 2026 |
| US NADAC | FOSAMAX PLUS D 70 MG-5600 UNIT | $52.51292 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Alendronic acid 70mg / Colecalciferol 70microgram tablets | £22.80 | 4 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.